RecruitingPhase 3NCT04803994
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Studying Fibrolamellar hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Principal Investigator
- Salah Eddin Al-Batran, Prof. Dr.Institut für Klinische Krebsforschung IKF GmbH, Frankfurt, Germany
- Intervention
- Atezolizumab(drug)
- Enrollment
- 434 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- LKH - Univ. Klinikum Graz, Graz, Austria
- Medzinische Universität Innsbruck, Innsbruck, Austria
- Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
- Ordensklinikum Linz, Linz, Austria
- Universitätsklinikum St. Pölten, Sankt Pölten, Austria
- Medizinische Universität Wien, Vienna, Austria
- Institut Sainte-Catherine, Avignon, France
- Hôpital Jean-Verdier Avicenne, Bobigny, France
- CHU Bordeaux, Bordeaux, France
- CHU Clermont-Ferrand CHU Estaing, Clermont-Ferrand, France
- Beaujon Hospital, Clichy, France
- CHU Grenoble, Grenoble, France
- Croix-Rousse Hopital, Lyon, France
- Saint Joseph Hopital - Marseille, Marseille, France
- Hôpital Universitaire Pitié Salpêtrière, Paris, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04803994 on ClinicalTrials.govOther trials for Fibrolamellar hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07521852A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCCTaiRx, Inc.
- RECRUITINGPHASE2NCT07504471Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver MetastasesRuijin Hospital
- RECRUITINGNCT07295275Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver ResectionWest China Hospital
- RECRUITINGPHASE2NCT07324824Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular CarcinomaSun Yat-sen University
- RECRUITINGEARLY PHASE1NCT07193862Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisNorthwell Health
- RECRUITINGPHASE1, PHASE2NCT07282184Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and InterventionTongji Hospital
- RECRUITINGNCT07170345Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionChinese Academy of Sciences
- RECRUITINGPHASE2NCT07099274Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital